{
  "id": 17786932,
  "title": "Pharma's next cash cows could be specialized treatments",
  "url": "https://urgent.news/2026/11/02/pharmas-next-cash-cows-could-be-specialized-treatments",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-02T10:30:04.000Z",
  "source": {
    "name": "Axios",
    "slug": "axios",
    "url": "https://www.axios.com/2026/11/02/pharma-profits-specialized-treatments-blockbuster-drugs"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pharmaceutical companies facing a steep patent cliff are concluding the key to future profits may be customized treatments tailored to patients' genes and lifestyles — not blockbusters aimed at large patient populations. Why it matters: The pivot could influence which diseases get treated in the decades to come, and how much the health system pays. The stakes are huge. More than $500 billion in…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}